About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon Quarterly Results
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
     
 
Financials

Financial Results

 
 
 

Current Financial Year 2017-18

  FY 17-18 Q1 H1 9M FY
  Notice Ad Notice Ad Q1 FY 2017-18 Notice Ad H1 FY 2017-18 - -
  Press Release Biocon_Q1 FY18_Press Release Biocon_Q1 FY18_Press Release - -
  Fact Sheet Biocon Fact Sheet - Summary Q1 FY18_Cr Biocon_Q1 FY18_Press Release - -
  Transcript of the Call Transcript Biocon Earnings 28 July 2017 Biocon_Q1 FY18_Press Release - -
  Newspaper Advertisement Transcript Biocon Earnings 28 July 2017 Biocon_press_releases_261017 - -
  Results Transcript Biocon Earnings 28 July 2017 Biocon_press_releases_261017 - -
  Investor Presentation - -

Consolidated Financial Performance (FY2016-FY2017)

As per IND-AS In Rs Crore, except growth numbers
Particulars  FY17 FY16
*Net Profit is pre-exceptional
Biocon 2,738 2,277
Small Molecules 1,587 1,387
Biologics 458 342
Branded Formulations 549 440
Licensing Income 144 108
Syngene: Research Services 1,138 1,060
Total Sales 3,876 3,337
Other Income 203 123
TOTAL REVENUE 4079 3460
EBITDA 1137 847
PBT (Before Exceptional Items) 850 591
Net Profit (Before Exceptional Items) 620 403
Exceptional Item (Net) (8) 147*
Net Profit  612 550
R&D Expenses in P&L 267 274
Gross R&D Spends 402 427
EBITDA Margin 28% 24%
Net Profit Margin 15% 16%
*Net Profit is pre-exceptional

Previous Year 2016-17 Financial Highlights

In Rs. Crore 
  FY 16-17 Q1 H1 9M FY
  Revenue 1033 2026 3117 4079
  EBITDA 304 581 906 1137
  Net Profit 167 311 485 612
  R&D Expenses in P&L 52 117 201 267
  Total R&D Spends 92 205 304 402
  EBITDA Margins 28% 29% 29% 28%
  Net Profit Margins 15% 15% 16% 15%
 
  * As per the new accounting standard: Ind-AS  
  FY15-16  FY15-16  FY14-15  FY13-14  FY12-13  FY11-12  FY10-11  FY09-10  FY08-09  FY07-08  FY06-07  FY05-06  FY04-05 

 
Quarterly Results
 FY17-18
 FY16-17
 FY15-16
 FY14-15
 FY13-14
 FY12-13
 FY11-12
 FY10-11
 FY09-10
 FY08-09
 FY07-08
 FY06-07
 FY05-06
 FY04-05
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved